Evaluation of radiochemical purities of routinely used radiopharmaceuticals: Three years’ experience of a single institute

Document Type : Original Article

Authors

Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar, Khyber Pakhtunkhwa, Pakistan

Abstract

Introduction: Radiochemical purity (RCP) is a routine quality control test carried out at nuclear medicine to determine the concentration of various chemical species present in the radiopharmaceuticals (RPs). The present work describes three years of experience in a single institute for the measurement of these impurities in the RPs preparations.
Methods: The RCP of different cold kit preparations were performed by chromatographic methods. Specifically, a small drop of the aliquot was spotted on the specific paper acting as the stationary phase and then developed in different solvents as mobile phases. The developed chromatograms were then quantified for various chemical species by Mini TLC scanner or well type counter.
Results:The retention factor (Rf) values for the different chemical species in the labeling of RP were measured by using single, double or triple solvent systems. It was observed that 2.70% of the kits had RCP less than the acceptable limit whereas 97.30% kits were found within the permissible levels.
Conclusion: Chromatographic techniques used for the assessment of RCP offer sufficiently good results for identification and separation of different chemical impurities.

Keywords

Main Subjects


  1. Zolle I. Technetium-99m pharmaceuticals: Preparation and quality control in nuclear medicine. Berlin Heidelberg: Springer; 2007.p. 123-143.
  2. Haleem RM, Salem MY, Fatahallah FA, Abdelfattah LE.  Quality in the pharmaceutical industry - A literature review. Saudi Pharm J. 2015 Oct;23(5):463-9. 
  3. Shah AS, Hameedullah,  Khan A,  Khan SU,  Shahid S. Comparison of 99Mo breakthrough levels in 99Mo/99mTc generator eluates from two manufacturers and its purification for nuclear medicine imaging. Pak J Radiol. 2009;19 (2);46-49.
  4. Maioli C, Luciniani G, Strinchini A, Tagliabue L, Del Sole A. Quality control on radiochemical purity in Technetium-99m radiopharmaceuticals labelling: three years of experience on 2280 procedures. Acta Biomed. 2017 Apr 28;88(1):49-56. 
  5. Huber L. Validation of analytical methods. Germany: Agilent technologies. Publication No. 5990-5140EN 2010.
  6. Ballinger JR, Blower PJ. Radiochemical purity testing of 99mTc-labelled radiopharmaceuticals: how much is enough?  Nucl Med Commun. 2011 Sep;32(9):761-3. 
  7. Neacsu B, Cimpeanu C, Barna C. Radionuclidic purity – An essential parameter in quality control of radiopharmaceuticals. Rom Rep Phys. 2013;65(1):155–167.
  8. Loveless VS. Quality control of compounded radiopharmaceuticals. Continuing education for nuclear pharmacists and nuclear medicine professionals. University of New Mexico Health Sciences Center. 2009.
  9. USP 36 NF 29: United States pharmacopeia [and] national formulary.  Rockville: United States Pharmacopeial Convention;2012.
  10. Faria DP, Marques FLN, Yamada AS, Miquelin CA. Evaluation of costs for quality control of [99mTc]technetium radiopharmaceuticals in Brazilian nuclear medicine centers. Radiol Bras 2011;44(1):47-51.
  11. Cunnane CM, O'Brien LM, Waight LA, Millar AM. Determination of the radiochemical purity of (99m) Tc medronate injection by thin layer chromatography on iTLC-SG: effect of medronate concentration on the value measured. J Labelled Comp Radiopharm. 2013 May 15;56(5):301-4.
  12. Ghahramani MR, Garibov AA, Agayev TN.  Determination of radiochemical purity of radioactive microspheres by paper chromatography. J Chromatogr Sep Tech. 2015;6:258.
  13. Mang'era K, Wong D2, Douglas D3, Franz K4, Biru T4. Evaluation of alternative rapid thin layer chromatography systems for quality control of technetium-99m radiopharmaceuticals. Appl Radiat Isot. 2014 Apr;86:57-62.
  14. de L. Santos PA, Andrade WG, Santos LAP, de Lima FF. Evaluation of different detection systems to determine the radiochemical purity of the technetium eluate and radiopharmaceutical sestamibi. The sixth International Nuclear Atlantic Conference; November 24-29; Brazil 2013.
  15. Sadeghpour H, Alavi M, Shahedi M, Entezarmahdi SM,  Sakhteman A. Evaluation of radiochemical purities of some radiopharmaceuticals in Shiraz Namazi teaching hospital. Trends Pharm Sci. 2015;1(1): 15-19.
  16. Vincenti LP, Samuel A, Zarb F. Establishing Radiopharmaceutical Standards at a Nuclear Medicine Unit in Malta. Int J Radiol Imaging Technol.  2016;2:012.
  17. Vallabhajosula S, Killeen RP, Osborne JR. Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors. Semin Nucl Med. 2010 Jul;40(4):220-41.
  18. Saha GB. Fundamentals of nuclear pharmacy. 4th ed. Cleveland, USA: Springer; 2004. p.150-158.
  19. Thomson N, Lai L,   Blower PJ.  99mTc sestamibi: what is the value of TLC quality control?  Nucl Med Commun 2005; 26(1):75.
  20. Norenberg JP, Vaidya MP, Hladik WB 3rd, Pathak DR, Born JL, Anderson TL, Carroll TR.  The effect of selected preparation variables on the radiochemical purity of 99mTc-sestamibi. J Nucl Med Technol. 2005 Mar;33(1):34-41.